Canada markets close in 4 hours 44 minutes

Aion Therapeutic Inc. (AION.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.09000.0000 (0.00%)
As of 10:06AM EDT. Market open.
Full screen
Previous Close0.0900
Open0.0950
Bid0.0850 x N/A
Ask0.0900 x N/A
Day's Range0.0900 - 0.0950
52 Week Range0.0600 - 0.1900
Volume170,550
Avg. Volume476,977
Market Cap10.632M
Beta (5Y Monthly)0.71
PE Ratio (TTM)N/A
EPS (TTM)-0.0450
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Aion Therapeutic Announces Closing of Non-Brokered Private Placement
    Newsfile

    Aion Therapeutic Announces Closing of Non-Brokered Private Placement

    Toronto, Ontario--(Newsfile Corp. - June 11, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 16,994,475 units (each, a "Unit") at a price of $0.0875 per Unit for gross proceeds of $1,487,016.56 (the "Offering"). The proceeds of the Offering will be used by the Company for general working capital purposes.Each Unit is comprised of one ...

  • Newsfile

    Aion Therapeutic Inc to Present at Benzinga Virtual Cannabis Capital Conference

    Detroit, Michigan--(Newsfile Corp. - June 2, 2021) - Aion Therapeutic Inc (CSE: AION) will be presenting at the Benzinga Cannabis Capital Conference taking place on June 3-4, 2021, with CEO J Graham Simmonds presenting at 4:55pm Eastern, Thursday June 3rd 2021. We invite our shareholders and all interested parties to join us for a full day of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: https://events.benzinga.com/ccc-free-registration.About Benzinga

  • Combined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways
    CNW Group

    Combined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways

    Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers.